In recent paper titled “Long term risk of death and readmission after hospital admission with covid-19 among older adults: retrospective cohort study”, the Medicare beneficiaries who were discharged alive after a covid-19 hospital admission had a higher post-discharge risk of death compared with historical influenza controls; this difference, however, was concentrated in the early post-discharge period. The risk of death for patients discharged after a covid-19 related hospital admission substantially declined over the course of the pandemic.
For more details, visit: BMJ https://www.bmj.com/content/382/bmj-2023-076222
Citation: Oseran AS, Song Y, Xu J, Dahabreh IJ, Wadhera RK, de Lemos JA, Das SR, Sun T, Yeh RW, Kazi DS. Long term risk of death and readmission after hospital admission with covid-19 among older adults: retrospective cohort study. bmj. 2023 Aug 9;382.
Will the New COVID-19 Vaccine Work Against the BA.2.86 Variant?
COVID-19 isn’t quite done with the world yet. Small surges of cases in the U.S., as well as upticks in COVID-19 hospitalizations over the summer, and new variants that weren’t around even three months ago, remind us that SARS-CoV-2 is still a health threat for the coming fall and winter.
The U.S. Food and Drug Administration (FDA) is expected to make a decision about which strain to target in the updated vaccine, which the agency says will be available in mid-to-late September. The FDA will be considering recommendations by the panel of independent vaccine experts it convened in June, which reviewed the latest data on an updated COVID-19 vaccine and which strains would likely be circulating in the fall and winter. The 21-member panel voted unanimously to update the next COVID-19 vaccine, and recommended moving from the current bivalent shot that targets two Omicron variants, BA.4 and BA.5, to now include a single XBB strain. The agency is still deciding which specific XBB strain the new vaccine will incorporate, although at the time, the dominant strain causing new infections was XBB.1.5.
For more, visit the source: https://time.com/6308418/ba-2-86-covid-19-variant-vaccine/
public health india 